Novo Nordisk (NVO) announced Saturday that its pending acquisition of three Catalent (NYSE:CTLT) production sites is expected to close within days as its parent entity satisfied all regulatory ...

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also ...

As a result, to meet growing demand, Novo Nordisk acquired Catalent for $16.5 billion in 2024. However, let's return to the discussion of how Novo Nordisk's EPS has changed and what to expect in 2025.

The Danish investment company Novo Nordisk A/S has received approval from the US Federal Trade Commission (FTC) to acquire the production assets of Catalent Inc., one of the world's largest ...

Novo Nordisk also reported the acquisition of three manufacturing sites from Novo Holdings A/S following the finalization of Novo Holdings' acquisition of Catalent, Inc. - a global contract ...

Moreover, free cash flow turned negative at minus DKK14.7 billion, largely due to heavy capital expenditures and the Catalent acquisition. Despite these challenges, Novo Nordisk remains well ...

In December, Novo Holdings, an investment foundation of Novo Nordisk, acquired three manufacturing sites in Catalent to expand its production capacity. CEO Lars Fruergaard Jørgensen commented ...

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter ... and the closing of the Catalent deal at the end of 2024 that will add three new sites. The company will now have 14 manufacturing ...

Novo Nordisk AS (NYSE:NVO) maintained its leadership in the GLP-1 market, serving nearly two-thirds of all patients on GLP-1 treatments. The company completed the acquisition of Catalent sites ...

Novo Nordisk NVO shares have lost 21% in the past ... primarily driven by increased sales of Wegovy and Ozempic. The closing of the Catalent deal in December last year is also expected to help ...